RECRUITINGOBSERVATIONAL
Identify microRNAs in Cachexia in Pancreatic Carcinoma
Pilot Trial to Identify microRNAs in Cachexia in Patients With Pancreatic Carcinoma
About This Trial
The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups.
Who May Be Eligible (Plain English)
Who May Qualify:
1. Male or female patient, who is ≥ 18 years old at the time of willing to sign a consent form.
2. Patients with operable pancreatic tumors diagnosed in the last 12 months prior to consent with clinical discretion or pathology confirmed as adenocarcinoma.
3. Patient has stage I or higher disease who is considered a candidate for surgical resection of pancreatic cancer, with or without neoadjuvant chemotherapy.
4. Ability to provide written willing to sign a consent form and HIPAA authorization.
Who Should NOT Join This Trial:
1. Patients with pancreatic adenocarcinoma who do not meet the criteria for surgical resection.
2. Patient has cancer diagnosis other than primary pancreatic adenocarcinoma.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
1. Male or female patient, who is ≥ 18 years old at the time of informed consent.
2. Patients with operable pancreatic tumors diagnosed in the last 12 months prior to consent with clinical discretion or pathology confirmed as adenocarcinoma.
3. Patient has stage I or higher disease who is considered a candidate for surgical resection of pancreatic cancer, with or without neoadjuvant chemotherapy.
4. Ability to provide written informed consent and HIPAA authorization.
Exclusion Criteria:
1. Patients with pancreatic adenocarcinoma who do not meet the criteria for surgical resection.
2. Patient has cancer diagnosis other than primary pancreatic adenocarcinoma.
Treatments Being Tested
OTHER
Pancreatic cancer microRNA and messenger RNA expression.
Tumor specimens from pancreatic patients will be analyzed for markers associated with muscle loss.
Locations (1)
Stephenson Cancer Center
Oklahoma City, Oklahoma, United States